Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease

Novalia Pishesha(Boston Children's Hospital), Angelina M. Bilate(Whitehead Institute for Biomedical Research), Marsha C. Wibowo(Whitehead Institute for Biomedical Research), Nai-Jia Huang(Whitehead Institute for Biomedical Research), Zeyang Li(Boston Children's Hospital), Rhogerry Deshycka(Whitehead Institute for Biomedical Research), Djenet Bousbaine(Boston Children's Hospital), Hojun Li(Whitehead Institute for Biomedical Research), Heide Christine Patterson(Whitehead Institute for Biomedical Research), Stephanie K. Dougan(Whitehead Institute for Biomedical Research), Takeshi Maruyama(Whitehead Institute for Biomedical Research), Harvey F. Lodish(Whitehead Institute for Biomedical Research), Hidde L. Ploegh(Boston Children's Hospital)
Proceedings of the National Academy of Sciences
March 7, 2017
Cited by 160Open Access
Full Text

Abstract

Significance Immune-mediated diseases are prevalent, debilitating, and costly. Unfortunately, current treatments rely on nonspecific immunosuppression, which also shuts down a protective immune response. To circumvent this, we exploited the noninflammatory natural means of clearance of red blood cells (RBCs), in combination with sortase-mediated RBC surface modification to display disease-associated autoantigens as RBCs’ own antigens. We found that this strategy holds promise for prophylaxis and therapy, as shown in a mouse model of multiple sclerosis and of type 1 diabetes.


Related Papers

No related papers found

Powered by citation graph analysis